Goldline Pharmaceutical IPO
Goldline Pharmaceutical is a BSE SME IPO is priced at ₹41–₹43 per share with an issue size of ₹11.61 crore. The IPO opens on May 12, 2026 and closes on May 14, 2026, with a lot size of 3000 shares and a minimum investment of ₹2,58,000.
Goldline Pharmaceutical Limited IPO
- IPO Dates
- May 12, 2026 – May 14, 2026
- Price band
- ₹41-43 per equity share
- Minimum Investment
- ₹2,58,000
- Issue size
- ₹11.61 Cr
- Lot size
- 3000
- Allotment Date
- May 15, 2026
- Listing
- May 19, 2026
- Listing At
- BSE SME
IPO timeline
-
May 12, 2026
Open Date
Completed
-
May 14, 2026
Close Date
Upcoming
-
May 15, 2026
Allotment Date
Upcoming
-
May 19, 2026
Listing Date
Upcoming
Goldline Pharmaceutical IPO Expected Premium (Grey Market Trend)
Goldline Pharmaceutical IPO GMP today is ₹8. Grey market premium (GMP) indicates expected listing sentiment.
Goldline Pharmaceutical IPO expected premium (also known as grey market premium or GMP) indicates current market sentiment and potential listing expectations.
Expected Premium provided in this website is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.
Goldline Pharmaceutical IPO Live Subscription Details
View Subscription DetailsGoldline Pharmaceutical IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.
Last updated:Goldline Pharmaceutical IPO Essentials
Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO is priced at ₹41-43 per share with a total issue size of 11.61 crore. The IPO has a lot size of 3000 shares and will be listed on BSE SME.
- Issue price
- ₹41-43 per equity share
- Lot size
- 3000 shares
- Face value
- ₹10 Per Equity Share
- Issue size
- 27,00,000 shares(agg. up to ₹11.61 Cr)
- Total issue size
- 27,00,000 shares
(aggregating up to ₹11.61 crore) - Fresh issue
- 27,00,000 shares
(aggregating up to ₹11.61 crore) - Listing at
- BSE SME
- Listing date
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead manager
-
Cumulative Capital Pvt.Ltd.
Market Lot Size
Investors can bid for a minimum of 6,000 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual (min) | 2 | 6,000 | ₹2,58,000 |
| Individual(max) | 2 | 6,000 | ₹2,58,000 |
| sHNI(min) | 3 | 9,000 | ₹3,87,000 |
| sHNI(max) | 7 | 21,000 | ₹9,03,000 |
| sHNI(min) | 8 | 24,000 | ₹10,32,000 |
Goldline Pharmaceutical IPO Reservation
Goldline Pharmaceutical IPO reservation details show category-wise allocation of shares. Out of the total 2700000 shares, approximately 20% are reserved for QIB, 14.44% for NII, 33.33% for retail investors, 5.11% for market maker, and 27.11% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 732000 (27.11%) | |
| Market Maker Shares Offered | 138000 (5.11%) | |
| QIB Shares Offered | 540000 (20%) | |
| NII (HNI) Shares Offered | 390000 (14.44%) | |
| bHNI > ₹10L | 260000 (9.39%) | 29 |
| sHNI < ₹10L | 132000 (4.85%) | 14 |
| Individual Shares Offered | 900000 (33.33%) | 150 |
| Total Shares Offered | 2700000 (100%) |
Goldline Pharmaceutical IPO Analytics
Goldline Pharmaceutical IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Goldline Pharmaceutical IPO Subscription Status
Goldline Pharmaceutical IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO is currently subscribed 22.35x, indicating strong demand across investor categories.
| As on | QIB |
NII
bHNI
sHNI
|
Individual | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 5,40,000 |
3,90,000
2,60,000
1,32,000
|
9,00,000 | 18,30,000 |
|
Day 1
12-05-26 05:00 PM
|
1.31 x |
24.46x
22.35x
28.25x
|
34.07 x | 22.35 x |
Goldline Pharmaceutical Valuations
Earnings
- EPS Pre IPO
- ₹4.11/-
- EPS Post IPO
- ₹3.09/-
- P/E Pre IPO
- 10.47
- P/E Post IPO
- 13.93
Returns
- ROE
- 35.84%
- ROCE
- 38.46%
- RoNW
- 27.38%
- PAT Margin
- 10.10%
Fundamentals
- Debt / Equity
- 1.50
- Price / Book
- 3.47
- Market Cap
- ₹41.28 Cr.
Goldline Pharmaceutical Financials( In Crs.)
| 31-Dec-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 | |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Revenue | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| Net Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves & Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Goldline Pharmaceutical Company & Offer Insights
About Goldline Pharmaceutical
Goldline Pharmaceuticals has engaged itself in marketing pharmaceutical products branded as 'Goldline'. The product line of Goldline can be categorized into five groups:
Goldline Pharma: It includes a range of 42 products for specialties including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.
Goldline Cardinal: It consists of a range of 54 products for the Specialty division in medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.
Goldline Aayushman: It consists of a range of 18 products for the Specialty division in medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.
Goldline InLife: It includes a range of 22 products for the Specialty division in medical fields such as Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.
Goldline Wellness: It consists of a range of 10 products for Supportive care for patients undergoing chemotherapy for their illness.
As the company does not manufacture any products, it collaborates with third parties which manufacture medicines according to market analysis and product specifications of the company.
The firm does not produce any products but rather works with third-party producers who manufacture their products as per the firm's market research and product descriptions, thus ensuring quality and regulatory compliance.Their products are all marketed and sold using the Goldline brand name by our distribution partners who distribute the products to retailers and wholesalers. Currently, the firm uses 15 producers and 7 distribution firms for selling its products, and it also helps hospitals and healthcare institutions in procurement and supplies.
The firm sells products in the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Goldline Pharmaceutical Promoter(s)
Amol Laxmikant Mujumdar, Swapan Premprakash Khandelwal are the company's promoters of Goldline Pharmaceutical.
Goldline Pharmaceutical IPO Issue Objectives
- •
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
- •
- General corporate purposes
Contact Information
Contact Details
Goldline Pharmaceutical
+91 712 2786666
103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra - 440015.
Registrar Contact Details
Bigshare Services Pvt Ltd
+91-22-6263 8200
Frequently Asked Questions
Click any question to reveal the answer
Goldline Pharmaceutical IPO is a book-built IPO worth ₹11.61 crore. The price band is ₹41–₹43 per share. The IPO opens on May 12, 2026 and closes on May 14, 2026. It will be listed on BSE SME Platform. Bigshare Services Pvt. Ltd. is the registrar.
The price band of Goldline Pharmaceutical IPO is ₹41 to ₹43 per share.
The lot size of Goldline Pharmaceutical IPO is 3000 shares.
The minimum investment for Goldline Pharmaceutical IPO is approximately ₹2,58,000 based on the upper price band .
Goldline Pharmaceutical IPO opens on May 12, 2026 and closes on May 14, 2026.
The allotment date of Goldline Pharmaceutical IPO is May 15, 2026.
Goldline Pharmaceutical IPO is expected to be listed on May 19, 2026, on BSE SME Platform.
The Grey Market Premium (GMP) for Goldline Pharmaceutical IPO is ₹8 as of May 12, 2026. Based on the upper price band of ₹43, the estimated listing price is ₹51, representing a potential gain of approximately 19%.
Goldline Pharmaceutical IPO valuation snapshot: P/E 13.93, EPS ₹3.09/-, P/B 3.47, RoNW 27.38%, and market cap ₹41.28 Cr.
To apply for Goldline Pharmaceutical IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Goldline Pharmaceutical IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Goldline Pharmaceutical IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Goldline Pharmaceutical IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Goldline Pharmaceutical IPO allotment status on IPO Ji for quick and easy access.
|
Offer Date |
May 12 - May 14, 2026 |
|
Offer Price |
₹ 41-43 |
|
Lot Size |
3000 |
Please login to Apply IPO